Published in Proc Natl Acad Sci U S A on February 03, 2003
Assess 123-I IMPY and SPECT Imaging as a Tool to Detect β-Amyloid in the Brain | NCT00287248
Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease. N Engl J Med (2014) 6.50
Passive immunotherapy against Abeta in aged APP-transgenic mice reverses cognitive deficits and depletes parenchymal amyloid deposits in spite of increased vascular amyloid and microhemorrhage. J Neuroinflammation (2004) 2.67
A recessive mutation in the APP gene with dominant-negative effect on amyloidogenesis. Science (2009) 2.30
The microglial "activation" continuum: from innate to adaptive responses. J Neuroinflammation (2005) 2.23
Can Alzheimer disease be prevented by amyloid-beta immunotherapy? Nat Rev Neurol (2010) 2.20
The peripheral benzodiazepine receptor (Translocator protein 18kDa) in microglia: from pathology to imaging. Prog Neurobiol (2006) 2.10
Anti-amyloid-beta immunotherapy in Alzheimer's disease: relevance of transgenic mouse studies to clinical trials. J Alzheimers Dis (2008) 2.01
Active and passive immunotherapy for neurodegenerative disorders. Annu Rev Neurosci (2008) 2.01
Anti-Abeta42- and anti-Abeta40-specific mAbs attenuate amyloid deposition in an Alzheimer disease mouse model. J Clin Invest (2005) 1.96
Ultrasound enhanced delivery of molecular imaging and therapeutic agents in Alzheimer's disease mouse models. PLoS One (2008) 1.95
Neuroprotective natural antibodies to assemblies of amyloidogenic peptides decrease with normal aging and advancing Alzheimer's disease. Proc Natl Acad Sci U S A (2009) 1.39
Intracerebroventricular amyloid-beta antibodies reduce cerebral amyloid angiopathy and associated micro-hemorrhages in aged Tg2576 mice. Proc Natl Acad Sci U S A (2009) 1.37
Amyloid-beta vaccination, but not nitro-nonsteroidal anti-inflammatory drug treatment, increases vascular amyloid and microhemorrhage while both reduce parenchymal amyloid. Neuroscience (2006) 1.31
Alzheimer's disease peptide epitope vaccine reduces insoluble but not soluble/oligomeric Abeta species in amyloid precursor protein transgenic mice. J Neurosci (2007) 1.31
Molecular basis for passive immunotherapy of Alzheimer's disease. Proc Natl Acad Sci U S A (2007) 1.26
CNS expression of anti-inflammatory cytokine interleukin-4 attenuates Alzheimer's disease-like pathogenesis in APP+PS1 bigenic mice. FASEB J (2010) 1.25
Cytokine-mediated inhibition of fibrillar amyloid-beta peptide degradation by human mononuclear phagocytes. J Immunol (2008) 1.23
AAV-tau mediates pyramidal neurodegeneration by cell-cycle re-entry without neurofibrillary tangle formation in wild-type mice. PLoS One (2009) 1.23
Identification of low molecular weight pyroglutamate A{beta} oligomers in Alzheimer disease: a novel tool for therapy and diagnosis. J Biol Chem (2010) 1.22
Impact of amyloid imaging on drug development in Alzheimer's disease. Nucl Med Biol (2007) 1.19
Parkin promotes intracellular Abeta1-42 clearance. Hum Mol Genet (2009) 1.18
Immunotherapy for Alzheimer's disease. Proc Natl Acad Sci U S A (2004) 1.17
Abeta42 gene vaccine prevents Abeta42 deposition in brain of double transgenic mice. J Neurol Sci (2007) 1.17
Involvement of Fc receptors in disorders of the central nervous system. Neuromolecular Med (2009) 1.15
DNA prime-protein boost increased the titer, avidity and persistence of anti-Abeta antibodies in wild-type mice. Gene Ther (2009) 1.13
Immunotherapeutic approaches for Alzheimer's disease. Neuron (2015) 1.13
Antibody uptake into neurons occurs primarily via clathrin-dependent Fcγ receptor endocytosis and is a prerequisite for acute tau protein clearance. J Biol Chem (2013) 1.12
Generation and characterization of the humoral immune response to DNA immunization with a chimeric beta-amyloid-interleukin-4 minigene. Eur J Immunol (2003) 1.12
Morphological characterization of Thioflavin-S-positive amyloid plaques in transgenic Alzheimer mice and effect of passive Abeta immunotherapy on their clearance. Am J Pathol (2004) 1.11
Prototype Alzheimer's disease epitope vaccine induced strong Th2-type anti-Abeta antibody response with Alum to Quil A adjuvant switch. Vaccine (2005) 1.09
Amyloid-beta immunotherapy for Alzheimer's disease. CNS Neurol Disord Drug Targets (2010) 1.07
DNA beta-amyloid(1-42) trimer immunization for Alzheimer disease in a wild-type mouse model. JAMA (2009) 1.07
Targets for AD treatment: conflicting messages from γ-secretase inhibitors. J Neurochem (2011) 1.05
Anti-Abeta single-chain antibody delivery via adeno-associated virus for treatment of Alzheimer's disease. Neurobiol Dis (2006) 1.04
Immunotherapy for Alzheimer's disease. Biochem Pharmacol (2014) 1.04
Neuritic deposits of amyloid-beta peptide in a subpopulation of central nervous system-derived neuronal cells. Mol Cell Biol (2006) 1.03
Novel Abeta peptide immunogens modulate plaque pathology and inflammation in a murine model of Alzheimer's disease. J Neuroinflammation (2005) 1.03
Simulating oligomerization at experimental concentrations and long timescales: A Markov state model approach. J Chem Phys (2008) 1.02
Abeta DNA vaccination for Alzheimer's disease: focus on disease prevention. CNS Neurol Disord Drug Targets (2010) 1.02
Evaluating amyloid-β oligomers in cerebrospinal fluid as a biomarker for Alzheimer's disease. PLoS One (2013) 1.01
FGF2 gene transfer restores hippocampal functions in mouse models of Alzheimer's disease and has therapeutic implications for neurocognitive disorders. Proc Natl Acad Sci U S A (2011) 1.00
Immunotherapy for Alzheimer's disease: past, present and future. Front Aging Neurosci (2014) 0.99
Localization of a conformational epitope common to non-native and fibrillar immunoglobulin light chains. Biochemistry (2007) 0.98
MER5101, a novel Aβ1-15:DT conjugate vaccine, generates a robust anti-Aβ antibody response and attenuates Aβ pathology and cognitive deficits in APPswe/PS1ΔE9 transgenic mice. J Neurosci (2013) 0.98
Intracranial administration of deglycosylated C-terminal-specific anti-Abeta antibody efficiently clears amyloid plaques without activating microglia in amyloid-depositing transgenic mice. J Neuroinflammation (2006) 0.97
APOE-ε2 and APOE-ε4 correlate with increased amyloid accumulation in cerebral vasculature. J Neuropathol Exp Neurol (2013) 0.96
Nasal inoculation of an adenovirus vector encoding 11 tandem repeats of Abeta1-6 upregulates IL-10 expression and reduces amyloid load in a Mo/Hu APPswe PS1dE9 mouse model of Alzheimer's disease. J Gene Med (2007) 0.96
Mechanisms of action of non-steroidal anti-inflammatory drugs for the prevention of Alzheimer's disease. CNS Neurol Disord Drug Targets (2010) 0.95
Structural correlates of antibodies associated with acute reversal of amyloid beta-related behavioral deficits in a mouse model of Alzheimer disease. J Biol Chem (2009) 0.94
A peptide prime-DNA boost immunization protocol provides significant benefits as a new generation Aβ42 DNA vaccine for Alzheimer disease. J Neuroimmunol (2012) 0.94
Distinct Therapeutic Mechanisms of Tau Antibodies: Promoting Microglial Clearance Versus Blocking Neuronal Uptake. J Biol Chem (2015) 0.91
Developing therapeutic vaccines against Alzheimer's disease. Expert Rev Vaccines (2015) 0.90
Papillomavirus-like particles are an effective platform for amyloid-beta immunization in rabbits and transgenic mice. J Immunol (2006) 0.90
Boosting with intranasal dendrimeric Abeta1-15 but not Abeta1-15 peptide leads to an effective immune response following a single injection of Abeta1-40/42 in APP-tg mice. J Neuroinflammation (2006) 0.90
The immunotherapy of Alzheimer's disease. Immun Ageing (2004) 0.90
Structure-activity relationships in peptide modulators of β-amyloid protein aggregation: variation in α,α-disubstitution results in altered aggregate size and morphology. ACS Chem Neurosci (2010) 0.89
Rationale for peptide and DNA based epitope vaccines for Alzheimer's disease immunotherapy. CNS Neurol Disord Drug Targets (2009) 0.89
CD4 T cells in immunity and immunotherapy of Alzheimer's disease. Immunology (2013) 0.89
A fresh perspective from immunologists and vaccine researchers: Active vaccination strategies to prevent and reverse Alzheimer's disease. Alzheimers Dement (2015) 0.89
The immunological potency and therapeutic potential of a prototype dual vaccine against influenza and Alzheimer's disease. J Transl Med (2011) 0.87
Interleukin-1 receptor 1 knockout has no effect on amyloid deposition in Tg2576 mice and does not alter efficacy following Abeta immunotherapy. J Neuroinflammation (2006) 0.87
Alzheimer's disease and immunotherapy. Aging Dis (2013) 0.86
Targeting the proper amyloid-beta neuronal toxins: a path forward for Alzheimer's disease immunotherapeutics. Alzheimers Res Ther (2014) 0.86
Current concepts in therapeutic strategies targeting cognitive decline and disease modification in Alzheimer's disease. NeuroRx (2005) 0.85
Deglycosylated anti-Abeta antibody dose-response effects on pathology and memory in APP transgenic mice. J Neuroimmune Pharmacol (2008) 0.85
Microglial responses to amyloid beta peptide opsonization and indomethacin treatment. J Neuroinflammation (2005) 0.85
Crystal structure reveals conservation of amyloid-β conformation recognized by 3D6 following humanization to bapineuzumab. Alzheimers Res Ther (2014) 0.84
Selective targeting of microglia by quantum dots. J Neuroinflammation (2012) 0.84
Immunocytochemical characterization of Alzheimer disease hallmarks in APP/PS1 transgenic mice treated with a new anti-amyloid-β vaccine. Biomed Res Int (2013) 0.83
Vaccine Development to Treat Alzheimer's Disease Neuropathology in APP/PS1 Transgenic Mice. Int J Alzheimers Dis (2012) 0.82
Linear and conformation specific antibodies in aged beagles after prolonged vaccination with aggregated Abeta. Neurobiol Dis (2010) 0.81
ABCA7 Deficiency Accelerates Amyloid-β Generation and Alzheimer's Neuronal Pathology. J Neurosci (2016) 0.81
An anti-pyroglutamate-3 Aβ vaccine reduces plaques and improves cognition in APPswe/PS1ΔE9 mice. Neurobiol Aging (2015) 0.81
Restricted V gene usage and VH/VL pairing of mouse humoral response against the N-terminal immunodominant epitope of the amyloid β peptide. Mol Immunol (2010) 0.80
Virus-based nanoparticles as platform technologies for modern vaccines. Wiley Interdiscip Rev Nanomed Nanobiotechnol (2016) 0.80
Optimization of Gene Transfection in Murine Myeloma Cell Lines using Different Transfection Reagents. Avicenna J Med Biotechnol (2010) 0.79
CD45RB is a novel molecular therapeutic target to inhibit Abeta peptide-induced microglial MAPK activation. PLoS One (2008) 0.79
Perspectives in molecular imaging using staging biomarkers and immunotherapies in Alzheimer's disease. ScientificWorldJournal (2013) 0.78
Immunization with the SDPM1 peptide lowers amyloid plaque burden and improves cognitive function in the APPswePSEN1(A246E) transgenic mouse model of Alzheimer's disease. Neurobiol Dis (2010) 0.78
A coimmunization vaccine of Aβ42 ameliorates cognitive deficits without brain inflammation in an Alzheimer's disease model. Alzheimers Res Ther (2014) 0.78
Disease modifying therapies for Alzheimer's disease targeting Aβ oligomers: implications for therapeutic mechanisms. Biomed Res Int (2013) 0.78
Alzheimer's disease Advax(CpG)- adjuvanted MultiTEP-based dual and single vaccines induce high-titer antibodies against various forms of tau and Aβ pathological molecules. Sci Rep (2016) 0.77
Active and passive immunization strategies based on the SDPM1 peptide demonstrate pre-clinical efficacy in the APPswePSEN1dE9 mouse model for Alzheimer's disease. Neurobiol Dis (2013) 0.77
A new DNA vaccine fused with the C3d-p28 induces a Th2 immune response against amyloid-beta. Neural Regen Res (2013) 0.76
Alzheimer's disease: is a vaccine possible? Braz J Med Biol Res (2014) 0.76
Chaperone-like antibodies in neurodegenerative tauopathies: implication for immunotherapy. Cell Mol Neurobiol (2009) 0.76
Structural differences of amyloid-β fibrils revealed by antibodies from phage display. BMC Biotechnol (2015) 0.76
Immunotherapy with aducanumab restores calcium homeostasis in Tg2576 mice. J Neurosci (2016) 0.76
Generation and characterization of anti-AA amyloid-specific monoclonal antibodies. Front Immunol (2011) 0.76
Cellular Uptake of α-Synuclein Oligomer-Selective Antibodies is Enhanced by the Extracellular Presence of α-Synuclein and Mediated via Fcγ Receptors. Cell Mol Neurobiol (2016) 0.76
Yeast expressed foldable quadrivalent Aβ15 elicited strong immune response against Aβ without Aβ-specific T cell response in wild C57BL/6 mice. Hum Vaccin Immunother (2012) 0.75
The Peptide Vaccine Combined with Prior Immunization of a Conventional Diphtheria-Tetanus Toxoid Vaccine Induced Amyloid β Binding Antibodies on Cynomolgus Monkeys and Guinea Pigs. J Immunol Res (2015) 0.75
APOE Genotype Differentially Modulates Effects of Anti-Aβ, Passive Immunization in APP Transgenic Mice. Mol Neurodegener (2017) 0.75
Plasma Exosomes Spread and Cluster Around β-Amyloid Plaques in an Animal Model of Alzheimer's Disease. Front Aging Neurosci (2017) 0.75
Novel immunological approaches for the treatment of Alzheimer's disease. Zhongguo Xian Dai Shen Jing Ji Bing Za Zhi (2014) 0.75
Bapineuzumab for mild to moderate Alzheimer's disease: a meta-analysis of randomized controlled trials. BMC Neurol (2017) 0.75
Production of an anti-Aβ antibody fragment in Pichia pastoris and in vitro and in vivo validation of its therapeutic effect. PLoS One (2017) 0.75
MultiTEP platform-based DNA vaccines for alpha-synucleinopathies: preclinical evaluation of immunogenicity and therapeutic potency. Neurobiol Aging (2017) 0.75
Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature (1999) 12.95
Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat Med (2000) 8.89
Fc receptors. Annu Rev Immunol (1991) 7.92
FcR gamma chain deletion results in pleiotrophic effector cell defects. Cell (1994) 7.66
A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature (2001) 7.35
Isolation and quantification of soluble Alzheimer's beta-peptide from biological fluids. Nature (1992) 7.02
A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease. Nature (2001) 6.78
Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer's disease. Proc Natl Acad Sci U S A (2001) 5.60
Synthetic peptide vaccine design: synthesis and properties of a high-density multiple antigenic peptide system. Proc Natl Acad Sci U S A (1988) 5.52
Immunization reverses memory deficits without reducing brain Abeta burden in Alzheimer's disease model. Nat Neurosci (2002) 5.01
Amyloid precursor protein processing and A beta42 deposition in a transgenic mouse model of Alzheimer disease. Proc Natl Acad Sci U S A (1997) 4.92
Epitopes involved in antibody-mediated protection from Ebola virus. Science (2000) 4.92
Role of the B-cell response in recovery of mice from primary influenza virus infection. Immunol Rev (1997) 3.20
Non-Fc-mediated mechanisms are involved in clearance of amyloid-beta in vivo by immunotherapy. J Neurosci (2002) 2.44
Amyloid-beta immunotherapy for Alzheimer's disease: the end of the beginning. Nat Rev Neurosci (2002) 2.42
Disaggregation of Alzheimer beta-amyloid by site-directed mAb. Proc Natl Acad Sci U S A (1997) 2.35
Cutting edge: biasing immune responses by directing antigen to macrophage Fc gamma receptors. J Immunol (2002) 2.02
Immunization with a nontoxic/nonfibrillar amyloid-beta homologous peptide reduces Alzheimer's disease-associated pathology in transgenic mice. Am J Pathol (2001) 1.69
Intranasal interleukin-12 is a powerful adjuvant for protective mucosal immunity. J Infect Dis (1999) 1.39
Complement activation selectively potentiates the pathogenicity of the IgG2b and IgG3 isotypes of a high affinity anti-erythrocyte autoantibody. J Exp Med (2002) 1.39
Exact cleavage site of Alzheimer amyloid precursor in neuronal PC-12 cells. Neurosci Lett (1991) 1.26
N-terminal EFRH sequence of Alzheimer's beta-amyloid peptide represents the epitope of its anti-aggregating antibodies. J Neuroimmunol (1998) 1.09
Dosing in phase II trial of Alzheimer's vaccine suspended. Lancet Neurol (2002) 1.04
A roadmap for the prevention of dementia II: Leon Thal Symposium 2008. Alzheimers Dement (2009) 10.21
Physical performance measures in the clinical setting. J Am Geriatr Soc (2003) 7.67
A roadmap for the prevention of dementia: the inaugural Leon Thal Symposium. Alzheimers Dement (2008) 6.39
A regulatory mutation in IGF2 causes a major QTL effect on muscle growth in the pig. Nature (2003) 5.41
11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study. Lancet Neurol (2010) 5.03
Phosphorylation of Ser-129 is the dominant pathological modification of alpha-synuclein in familial and sporadic Lewy body disease. J Biol Chem (2006) 4.06
Anti-JC virus antibodies: implications for PML risk stratification. Ann Neurol (2010) 3.67
Alzheimer's disease: molecular understanding predicts amyloid-based therapeutics. Annu Rev Pharmacol Toxicol (2002) 3.62
Effects of alpha-synuclein immunization in a mouse model of Parkinson's disease. Neuron (2005) 3.20
The role of biomarkers in clinical trials for Alzheimer disease. Alzheimer Dis Assoc Disord (2006) 2.86
Aurora A phosphorylation of TACC3/maskin is required for centrosome-dependent microtubule assembly in mitosis. J Cell Biol (2005) 2.57
Non-Fc-mediated mechanisms are involved in clearance of amyloid-beta in vivo by immunotherapy. J Neurosci (2002) 2.44
Abeta species removal after abeta42 immunization. J Neuropathol Exp Neurol (2006) 2.25
Partial reduction of BACE1 has dramatic effects on Alzheimer plaque and synaptic pathology in APP Transgenic Mice. J Biol Chem (2007) 2.22
Passive immunization reduces behavioral and neuropathological deficits in an alpha-synuclein transgenic model of Lewy body disease. PLoS One (2011) 2.19
Building multisectoral partnerships for population health and health equity. Prev Chronic Dis (2010) 2.19
Transcranial magnetic stimulation of the brain: guidelines for pain treatment research. Pain (2015) 2.11
Possible involvement of pregnane X receptor-enhanced CYP24 expression in drug-induced osteomalacia. J Clin Invest (2005) 1.96
Decreased adult hippocampal neurogenesis in the PDAPP mouse model of Alzheimer's disease. J Comp Neurol (2006) 1.96
ETV1 directs androgen metabolism and confers aggressive prostate cancer in targeted mice and patients. Genes Dev (2013) 1.87
Dentate gyrus volume is reduced before onset of plaque formation in PDAPP mice: a magnetic resonance microscopy and stereologic analysis. Proc Natl Acad Sci U S A (2003) 1.86
Beta-amyloid immunotherapy prevents synaptic degeneration in a mouse model of Alzheimer's disease. J Neurosci (2005) 1.85
Effect of statins on Alzheimer's disease biomarkers in cerebrospinal fluid. J Alzheimers Dis (2006) 1.82
Melanoma cell adhesion molecule identifies encephalitogenic T lymphocytes and promotes their recruitment to the central nervous system. Brain (2012) 1.78
Red blood cells are the major source of alpha-synuclein in blood. Neurodegener Dis (2008) 1.77
Granulocyte macrophage colony-stimulating factor--secreting allogeneic cellular immunotherapy for hormone-refractory prostate cancer. Clin Cancer Res (2007) 1.71
Immunotherapy reduces vascular amyloid-beta in PDAPP mice. J Neurosci (2008) 1.70
Cross-sectional association of 10 molecular markers of bone, cartilage, and synovium with disease activity and radiological joint damage in patients with hip osteoarthritis: the ECHODIAH cohort. J Rheumatol (2005) 1.69
Detection of survivin-expressing circulating cancer cells (CCCs) in peripheral blood of patients with gastric and colorectal cancer reveals high risks of relapse. Ann Surg Oncol (2008) 1.62
The oncolytic poxvirus JX-594 selectively replicates in and destroys cancer cells driven by genetic pathways commonly activated in cancers. Mol Ther (2011) 1.59
A sequence-based map of the nine genes of the human interleukin-1 cluster. Genomics (2002) 1.58
Polo-like kinase 2 (PLK2) phosphorylates alpha-synuclein at serine 129 in central nervous system. J Biol Chem (2008) 1.54
Engineering antibody heavy chain CDR3 to create a phage display Fab library rich in antibodies that bind charged carbohydrates. J Immunol (2008) 1.52
Abeta42 immunization in Alzheimer's disease generates Abeta N-terminal antibodies. Ann Neurol (2005) 1.51
Histone demethylase Lsd1 represses hematopoietic stem and progenitor cell signatures during blood cell maturation. Elife (2013) 1.44
Quantitative magnetic resonance perfusion imaging detects anatomic and physiologic coronary artery disease as measured by coronary angiography and fractional flow reserve. J Am Coll Cardiol (2007) 1.43
Semitendinosus tendon graft versus a modified Weaver-Dunn procedure for acromioclavicular joint reconstruction in chronic cases: a prospective comparative study. Am J Sports Med (2008) 1.42
Progress in the active immunotherapeutic approach to Alzheimer's disease: clinical investigations into AN1792-associated meningoencephalitis. Neurodegener Dis (2008) 1.39
Amyloid deposition in the hippocampus and entorhinal cortex: quantitative analysis of a transgenic mouse model. Proc Natl Acad Sci U S A (2003) 1.37
Sampling nucleotide diversity in cotton. BMC Plant Biol (2009) 1.34
Mice as models: transgenic approaches and Alzheimer's disease. J Alzheimers Dis (2006) 1.32
Passive immunotherapy rapidly increases structural plasticity in a mouse model of Alzheimer disease. Neurobiol Dis (2008) 1.29
An antibody delivery system for regulated expression of therapeutic levels of monoclonal antibodies in vivo. Mol Ther (2007) 1.26
Abeta immunotherapy: intracerebral sequestration of Abeta by an anti-Abeta monoclonal antibody 266 with high affinity to soluble Abeta. J Neurosci (2009) 1.24
Competition between α-actinin and Ca²⁺-calmodulin controls surface retention of the L-type Ca²⁺ channel Ca(V)1.2. Neuron (2013) 1.23
Identification of genetically modified Maraba virus as an oncolytic rhabdovirus. Mol Ther (2010) 1.22
Selective vulnerability of dentate granule cells prior to amyloid deposition in PDAPP mice: digital morphometric analyses. Proc Natl Acad Sci U S A (2004) 1.20
Pulvinar neurons reveal neurobiological evidence of past selection for rapid detection of snakes. Proc Natl Acad Sci U S A (2013) 1.20
Current progress in beta-amyloid immunotherapy. Curr Opin Immunol (2004) 1.18
Neutralization of soluble, synaptotoxic amyloid β species by antibodies is epitope specific. J Neurosci (2012) 1.16
Vascular alterations in PDAPP mice after anti-Aβ immunotherapy: Implications for amyloid-related imaging abnormalities. Alzheimers Dement (2013) 1.16
Alpha2beta1 and alphaVbeta1 integrin signaling pathways mediate amyloid-beta-induced neurotoxicity. Neurobiol Aging (2006) 1.14
GPR93 activation by protein hydrolysate induces CCK transcription and secretion in STC-1 cells. Am J Physiol Gastrointest Liver Physiol (2007) 1.13
Amyloid beta-protein precursor juxtamembrane domain regulates specificity of gamma-secretase-dependent cleavages. J Biol Chem (2007) 1.13
Spouse caregivers of kidney transplant patients: quality of life and psychosocial outcomes. Prog Transplant (2010) 1.12
Morphological characterization of Thioflavin-S-positive amyloid plaques in transgenic Alzheimer mice and effect of passive Abeta immunotherapy on their clearance. Am J Pathol (2004) 1.11